Inactivation of HNSCC cells by 90Y-labeled cetuximab strictly depends on the number of induced DNA double-strand breaks.
Standard
Inactivation of HNSCC cells by 90Y-labeled cetuximab strictly depends on the number of induced DNA double-strand breaks. / Saker, Jarob; Kriegs, Malte; Zenker, Martin; Heldt, Jan-Martin; Eke, Iris; Pietzsch, Hans-Jürgen; Grénman, Reidar; Cordes, Nils; Petersen, Cordula; Baumann, Michael; Steinbach, Jörg; Dikomey, Ekkehard; Kasten-Pisula, Ulla.
In: J NUCL MED, Vol. 54, No. 3, 3, 2013, p. 416-423.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Inactivation of HNSCC cells by 90Y-labeled cetuximab strictly depends on the number of induced DNA double-strand breaks.
AU - Saker, Jarob
AU - Kriegs, Malte
AU - Zenker, Martin
AU - Heldt, Jan-Martin
AU - Eke, Iris
AU - Pietzsch, Hans-Jürgen
AU - Grénman, Reidar
AU - Cordes, Nils
AU - Petersen, Cordula
AU - Baumann, Michael
AU - Steinbach, Jörg
AU - Dikomey, Ekkehard
AU - Kasten-Pisula, Ulla
PY - 2013
Y1 - 2013
N2 - UNLABELLED: Radioimmunotherapy is considered to have great potential for efficient and highly specific treatment of tumors. The aim of this study was to determine the efficacy of radioimmunotherapy when using (90)Y-labeled cetuximab and to determine to what degree induction and repair of DNA double-strand breaks (DSBs) are decisive for this approach.METHODS: This study was performed with 9 cell lines of squamous cell carcinoma of the head and neck (HNSCC) differing strongly in epidermal growth factor receptor (EGFR) expression. The radionuclide (90)Y was coupled by the chelator trans-cyclohexyl-diethylene-triamine-pentaacetic acid (CHX-A″-DTPA)/linker construct to the EGFR-directed antibody cetuximab to yield (90)Y-Y-CHX-A″-DTPA-cetuximab with a specific activity of approximately 1.2 GBq/mg. EGFR expression was determined by immunofluorescence and Western blotting, cetuximab binding by fluorescence-activated cell sorter analysis, the number of DSBs by immunofluorescence staining γH2AX/53BP1-positive repair foci, and cell survival by colony formation. Results: For the 9 HNSCC cell lines, cetuximab binding correlated with the amount of EGFR present in the cell membrane (r(2) = 0.967, P < 0.001). When cells were exposed to (90)Y-Y-CHX-A″-DTPA-cetuximab, the number of induced DSBs increased linearly with time (r(2) = 0.968, P = 0.016). This number was found to correlate with the amount of membranous EGFR (r(2) = 0.877, P = 0.006). Most DSBs were repaired during incubation at 37°C, but the small number of remaining DSBs still correlated with the amount of membranous EGFR (24 h: r(2) = 0.977, P < 0.001; 48 h: r(2) = 0.947, P < 0.001). Exposure to (90)Y-Y-CHX-A″-DTPA-cetuximab also resulted in efficient cell killing, whereby the extent of cell killing correlated strongly with the respective number of remaining DSBs (r(2) = 0.989, P < 0.001) and with the amount of membranous EGFR (r(2) = 0.967, P < 0.001). No cell killing was observed for UTSCC15 cells with low EGFR expression, in contrast to the strong reduction of 86% measured for UTSCC14 cells showing a strong overexpression of EGFR.CONCLUSION: (90)Y-Y-CHX-A″-DTPA-cetuximab affected cell survival through the induction of DSBs. This treatment was especially efficient for HNSCC cells strongly overexpressing EGFR, whereas no effect was seen for cells with low levels of EGFR expression. Therefore, EGFR-directed radioimmunotherapy using (90)Y-Y-CHX-A″-DTPA-cetuximab appears to be a powerful tool that can be used to inactivate tumors with strong EGFR overexpression, which are often characterized by a pronounced radioresistance.
AB - UNLABELLED: Radioimmunotherapy is considered to have great potential for efficient and highly specific treatment of tumors. The aim of this study was to determine the efficacy of radioimmunotherapy when using (90)Y-labeled cetuximab and to determine to what degree induction and repair of DNA double-strand breaks (DSBs) are decisive for this approach.METHODS: This study was performed with 9 cell lines of squamous cell carcinoma of the head and neck (HNSCC) differing strongly in epidermal growth factor receptor (EGFR) expression. The radionuclide (90)Y was coupled by the chelator trans-cyclohexyl-diethylene-triamine-pentaacetic acid (CHX-A″-DTPA)/linker construct to the EGFR-directed antibody cetuximab to yield (90)Y-Y-CHX-A″-DTPA-cetuximab with a specific activity of approximately 1.2 GBq/mg. EGFR expression was determined by immunofluorescence and Western blotting, cetuximab binding by fluorescence-activated cell sorter analysis, the number of DSBs by immunofluorescence staining γH2AX/53BP1-positive repair foci, and cell survival by colony formation. Results: For the 9 HNSCC cell lines, cetuximab binding correlated with the amount of EGFR present in the cell membrane (r(2) = 0.967, P < 0.001). When cells were exposed to (90)Y-Y-CHX-A″-DTPA-cetuximab, the number of induced DSBs increased linearly with time (r(2) = 0.968, P = 0.016). This number was found to correlate with the amount of membranous EGFR (r(2) = 0.877, P = 0.006). Most DSBs were repaired during incubation at 37°C, but the small number of remaining DSBs still correlated with the amount of membranous EGFR (24 h: r(2) = 0.977, P < 0.001; 48 h: r(2) = 0.947, P < 0.001). Exposure to (90)Y-Y-CHX-A″-DTPA-cetuximab also resulted in efficient cell killing, whereby the extent of cell killing correlated strongly with the respective number of remaining DSBs (r(2) = 0.989, P < 0.001) and with the amount of membranous EGFR (r(2) = 0.967, P < 0.001). No cell killing was observed for UTSCC15 cells with low EGFR expression, in contrast to the strong reduction of 86% measured for UTSCC14 cells showing a strong overexpression of EGFR.CONCLUSION: (90)Y-Y-CHX-A″-DTPA-cetuximab affected cell survival through the induction of DSBs. This treatment was especially efficient for HNSCC cells strongly overexpressing EGFR, whereas no effect was seen for cells with low levels of EGFR expression. Therefore, EGFR-directed radioimmunotherapy using (90)Y-Y-CHX-A″-DTPA-cetuximab appears to be a powerful tool that can be used to inactivate tumors with strong EGFR overexpression, which are often characterized by a pronounced radioresistance.
KW - Humans
KW - Cell Line, Tumor
KW - Antibodies, Monoclonal/therapeutic use
KW - RNA, Small Interfering/genetics
KW - DNA Breaks, Double-Stranded
KW - Radiation Tolerance
KW - Carcinoma, Squamous Cell/metabolism/pathology/radiotherapy
KW - Cell Death/radiation effects
KW - DNA Repair
KW - Head and Neck Neoplasms/metabolism/pathology/radiotherapy
KW - Immunoconjugates/therapeutic use
KW - Radioimmunotherapy
KW - Receptor, Epidermal Growth Factor/antagonists & inhibitors/genetics/immunology/metabolism
KW - Yttrium Radioisotopes/therapeutic use
KW - Humans
KW - Cell Line, Tumor
KW - Antibodies, Monoclonal/therapeutic use
KW - RNA, Small Interfering/genetics
KW - DNA Breaks, Double-Stranded
KW - Radiation Tolerance
KW - Carcinoma, Squamous Cell/metabolism/pathology/radiotherapy
KW - Cell Death/radiation effects
KW - DNA Repair
KW - Head and Neck Neoplasms/metabolism/pathology/radiotherapy
KW - Immunoconjugates/therapeutic use
KW - Radioimmunotherapy
KW - Receptor, Epidermal Growth Factor/antagonists & inhibitors/genetics/immunology/metabolism
KW - Yttrium Radioisotopes/therapeutic use
U2 - 10.2967/jnumed.111.101857
DO - 10.2967/jnumed.111.101857
M3 - SCORING: Journal article
C2 - 23345302
VL - 54
SP - 416
EP - 423
JO - J NUCL MED
JF - J NUCL MED
SN - 0161-5505
IS - 3
M1 - 3
ER -
